169 related articles for article (PubMed ID: 37766088)
1. Humoral Immunity in Immunosuppressed IBD Patients after the Third SARS-CoV-2 Vaccination: A Comparison with Healthy Control Subjects.
Vollenberg R; Lorentzen EU; Kühn J; Nowacki TM; Meier JA; Trebicka J; Tepasse PR
Vaccines (Basel); 2023 Aug; 11(9):. PubMed ID: 37766088
[TBL] [Abstract][Full Text] [Related]
2. Impaired Humoral Immunity with Concomitant Preserved T Cell Reactivity in IBD Patients on Treatment with Infliximab 6 Month after Vaccination with the SARS-CoV-2 mRNA Vaccine BNT162b2: A Pilot Study.
Vollenberg R; Tepasse PR; Lorentzen E; Nowacki TM
J Pers Med; 2022 Apr; 12(5):. PubMed ID: 35629116
[TBL] [Abstract][Full Text] [Related]
3. COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre, prospective, case-control study.
Alexander JL; Liu Z; Muñoz Sandoval D; Reynolds C; Ibraheim H; Anandabaskaran S; Saifuddin A; Castro Seoane R; Anand N; Nice R; Bewshea C; D'Mello A; Constable L; Jones GR; Balarajah S; Fiorentino F; Sebastian S; Irving PM; Hicks LC; Williams HRT; Kent AJ; Linger R; Parkes M; Kok K; Patel KV; Teare JP; Altmann DM; Goodhand JR; Hart AL; Lees CW; Boyton RJ; Kennedy NA; Ahmad T; Powell N;
Lancet Gastroenterol Hepatol; 2022 Nov; 7(11):1005-1015. PubMed ID: 36088954
[TBL] [Abstract][Full Text] [Related]
4. Humoral Immune Response in IBD Patients Three and Six Months after Vaccination with the SARS-CoV-2 mRNA Vaccines mRNA-1273 and BNT162b2.
Vollenberg R; Tepasse PR; Kühn JE; Hennies M; Strauss M; Rennebaum F; Schomacher T; Boeckel G; Lorentzen E; Bokemeyer A; Nowacki TM
Biomedicines; 2022 Jan; 10(1):. PubMed ID: 35052849
[TBL] [Abstract][Full Text] [Related]
5. Systemic and T cell-associated responses to SARS-CoV-2 immunisation in gut inflammation (STAR SIGN study): effects of biologics on vaccination efficacy of the third dose of mRNA vaccines against SARS-CoV-2.
Woelfel S; Dütschler J; König M; Graf N; Oikonomou V; Krieger C; Truniger S; Franke A; Eckhold A; Forsch K; Wyss J; Krupka N; Albrich W; Frei N; Geissler N; Schaub P; ; Friedrich M; Misselwitz B; Korte W; Bürgi JJ; Brand S
Aliment Pharmacol Ther; 2023 Jan; 57(1):103-116. PubMed ID: 36307899
[TBL] [Abstract][Full Text] [Related]
6. Anti-SARS-CoV-2 Vaccination and Antibody Response in Patients With Inflammatory Bowel Disease on Immune-modifying Therapy: Prospective Single-Tertiary Study.
Cerna K; Duricova D; Lukas M; Machkova N; Hruba V; Mitrova K; Kubickova K; Kostrejova M; Teplan V; Vasatko M; Kastylova K; Lukas M
Inflamm Bowel Dis; 2022 Oct; 28(10):1506-1512. PubMed ID: 34849919
[TBL] [Abstract][Full Text] [Related]
7. Humoral Immunogenicity After Vaccination Against SARS-CoV-2 Infection in Inflammatory Bowel Disease Patients Under Immunosuppressive Therapy: Should We Prioritize an Additional Booster Injection?
Macedo Silva V; Lima Capela T; Freitas M; Cúrdia Gonçalves T; Boal Carvalho P; Dias de Castro F; João Moreira M; Cotter J
Inflamm Bowel Dis; 2023 Feb; 29(2):268-273. PubMed ID: 36099059
[TBL] [Abstract][Full Text] [Related]
8. Use of Tumor Necrosis Factor-α Antagonists Is Associated With Attenuated IgG Antibody Response Against SARS-CoV-2 in Vaccinated Patients With Inflammatory Bowel Disease.
Otten AT; Bourgonje AR; Horinga PP; van der Meulen HH; Festen EAM; van Dullemen HM; Weersma RK; van Leer-Buter CC; Dijkstra G; Visschedijk MC
Front Immunol; 2022; 13():920333. PubMed ID: 35865529
[TBL] [Abstract][Full Text] [Related]
9. Antibody Responses to SARS-CoV-2 after Infection or Vaccination in Children and Young Adults with Inflammatory Bowel Disease.
Dailey J; Kozhaya L; Dogan M; Hopkins D; Lapin B; Herbst K; Brimacombe M; Grandonico K; Karabacak F; Schreiber J; Liang BT; Salazar JC; Unutmaz D; Hyams JS
medRxiv; 2021 Jun; ():. PubMed ID: 34159338
[TBL] [Abstract][Full Text] [Related]
10. STAR SIGN study: Evaluation of COVID-19 vaccine efficacy against the SARS-CoV-2 variants BQ.1.1 and XBB.1.5 in patients with inflammatory bowel disease.
Woelfel S; Dütschler J; König M; Dulovic A; Graf N; Junker D; Oikonomou V; Krieger C; Truniger S; Franke A; Eckhold A; Forsch K; Koller S; Wyss J; Krupka N; Oberholzer M; Frei N; Geissler N; Schaub P; ; Albrich WC; Friedrich M; Schneiderhan-Marra N; Misselwitz B; Korte W; Bürgi JJ; Brand S
Aliment Pharmacol Ther; 2023 Oct; 58(7):678-691. PubMed ID: 37571863
[TBL] [Abstract][Full Text] [Related]
11. Lower magnitude and faster waning of antibody responses to SARS-CoV-2 vaccination in anti-TNF-α-treated IBD patients are linked to lack of activation and expansion of cTfh1 cells and impaired B memory cell formation.
Garner-Spitzer E; Wagner A; Gudipati V; Schoetta AM; Orola-Taus M; Kundi M; Kunert R; Mayrhofer P; Huppa JB; Stockinger H; Carsetti R; Gattinger P; Valenta R; Kratzer B; Sehgal ANA; Pickl WF; Reinisch W; Novacek G; Wiedermann U
EBioMedicine; 2023 Oct; 96():104788. PubMed ID: 37672867
[TBL] [Abstract][Full Text] [Related]
12. Humoral immune response after different SARS-CoV-2 vaccination regimens.
Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A
BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798
[TBL] [Abstract][Full Text] [Related]
13. The gut microbiota and metabolome are associated with diminished COVID-19 vaccine-induced antibody responses in immunosuppressed inflammatory bowel disease patients.
Alexander JL; Mullish BH; Danckert NP; Liu Z; Olbei ML; Saifuddin A; Torkizadeh M; Ibraheim H; Blanco JM; Roberts LA; Bewshea CM; Nice R; Lin S; Prabhudev H; Sands C; Horneffer-van der Sluis V; Lewis M; Sebastian S; Lees CW; Teare JP; Hart A; Goodhand JR; Kennedy NA; Korcsmaros T; Marchesi JR; Ahmad T; Powell N
EBioMedicine; 2023 Feb; 88():104430. PubMed ID: 36634565
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of residual humoral immune response against SARS-CoV-2 by a surrogate virus neutralization test (sVNT) 9 months after BNT162b2 primary vaccination.
Pezzati L; Milazzo L; Carrozzo G; Kullmann C; Oreni L; Beltrami M; Caronni S; Lai A; Caberlotto L; Ottomano C; Antinori S; Ridolfo AL
J Infect Chemother; 2023 Jun; 29(6):624-627. PubMed ID: 36914095
[TBL] [Abstract][Full Text] [Related]
15. Reduced Serological Response to COVID-19 Vaccines in Patients with IBD is Further Diminished by TNF Inhibitor Therapy; Early Results of the VARIATION study [VAriability in Response in IBD Against SARS-COV-2 ImmunisatiON].
Doherty J; Morain NO; Stack R; Girod P; Tosetto M; Inzitiari R; Sheridan J; Cullen G; McDermott E; Buckley M; Horgan G; Mulcahy H; Ryan EJ; Daghfal D; Doran P; Morain CO; Doherty GA
J Crohns Colitis; 2022 Sep; 16(9):1354-1362. PubMed ID: 35176770
[TBL] [Abstract][Full Text] [Related]
16. Nationwide experiences with trough levels, durability, and disease activity among inflammatory bowel disease patients following COVID-19 vaccination.
Resál T; Bacsur P; Horváth M; Szántó K; Rutka M; Bálint A; Fábián A; Bor R; Szepes Z; Fekete J; Farkas K; Miheller P; Molnár T
Therap Adv Gastroenterol; 2023; 16():17562848231183529. PubMed ID: 37461738
[TBL] [Abstract][Full Text] [Related]
17. Reduced Serological Response to COVID-19 Booster Vaccine is Associated with Reduced B Cell Memory in Patients With Inflammatory Bowel Disease; VARIATION [VAriability in Response in IBD AgainsT SARS-COV-2 ImmunisatiON].
Doherty J; O'Morain N; Stack R; Tosetto M; Inzitiari R; O'Reilly S; Gu L; Sheridan J; Cullen G; Mc Dermott E; Buckley M; Horgan G; Mulcahy H; Walshe M; Ryan EJ; Gautier V; Prostko J; Frias E; Daghfal D; Doran P; O'Morain C; Doherty GA
J Crohns Colitis; 2023 Oct; 17(9):1445-1456. PubMed ID: 37018462
[TBL] [Abstract][Full Text] [Related]
18. Serological response to vaccination against coronavirus disease-19 in patients with inflammatory bowel disease.
Mathur A; Sahu S; Rai S; Ghoshal U; Ghoshal UC
Indian J Gastroenterol; 2023 Feb; 42(1):64-69. PubMed ID: 36598745
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity of BNT162b2 Vaccine Booster Dose in Patients With Inflammatory Bowel Disease Receiving Infliximab Combination Therapy: A Prospective Observational Study.
Shehab M; Alrashed F; Alfadhli A; Alsayegh A; Aldallal U; Alsayegh M; Cherian P; Alkhair I; Thanaraj TA; Channanath A; Dashti AA; Albanaw A; Ali H; Abu-Farha M; Abubaker J; Al-Mulla F
Front Med (Lausanne); 2022; 9():933996. PubMed ID: 35860742
[TBL] [Abstract][Full Text] [Related]
20. Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment.
Peeters M; Verbruggen L; Teuwen L; Vanhoutte G; Vande Kerckhove S; Peeters B; Raats S; Van der Massen I; De Keersmaecker S; Debie Y; Huizing M; Pannus P; Neven K; Ariën KK; Martens GA; Van Den Bulcke M; Roelant E; Desombere I; Anguille S; Goossens M; Vandamme T; van Dam P
ESMO Open; 2021 Oct; 6(5):100274. PubMed ID: 34597941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
